Introduction {#Sec1}
============

Despite major advances in the treatment of childhood cancer, cancer remains a common cause of death for children \>1 year of age \[[@CR1]\]. Twenty-two percent of all pediatric cancers are CNS tumors. Pediatric patients with relapsed cancers of the CNS have a poor prognosis, and therefore novel therapies for these patients are urgently needed. Immunotherapy against brain tumors presents unique challenges since the brain is considered an immune privileged site. However, recent studies demonstrated that the immune cells have access to the brain in spite of the blood-brain barrier \[[@CR2], [@CR3]\]. Within malignant brain tumors the blood-brain barrier is generally considered non-functional. Progress in our understanding of immune responses to CNS tumors have already led to novel clinical applications \[[@CR4], [@CR5]\]. Most experience has been obtained with immunotherapeutic trials with dendritic cell vaccinations, as reviewed by De Vleeschouwer et al. \[[@CR6]\].

Immunotherapy is an attractive therapeutic option for pediatric cancer patients because of its mild toxicity, and because the child's immune system is more potent and flexible compared to adults \[[@CR7], [@CR8]\]. However, implementation of immunotherapy in pediatric oncology has been hampered by the lack of known tumor-specific antigens on pediatric tumors.

Cancer-germline genes (CGGs) are expressed in a wide range of human tumors and have a highly restricted expression pattern in normal tissues \[[@CR9], [@CR10]\]. Antigens encoded by CGGs have been extensively studied because of their immunogenicity, tumor specificity, and their expression in a significant proportion of adult tumors of various histological types. Recently, we have shown that CGGs are expressed in a large percentage of pediatric extra-cranial solid tumors \[[@CR11]\].

The aim of this study was to analyze CGG expression in pediatric brain tumors. We report the results of a quantitative real-time PCR analysis of the expression of 12 CGGs in a panel of medulloblastomas, ependymomas, tumors of the choroid plexus and astrocytic tumors.

Materials and methods {#Sec2}
=====================

Tumor samples {#Sec3}
-------------

Fresh-frozen tumor samples were available at the Department of Pathology at the Radboud University Nijmegen Medical Centre. All samples were from pediatric patients (0--19-years-old) with a brain tumor diagnosed at the Department of Pediatric Hemato-Oncology. Sections of the frozen samples were stained with hematoxylin-eosin and reviewed by the pathologist to verify tumor histology and to evaluate the percentage of tumor cells. Samples were only considered for study if the contents of tumor cells was ≥80%.

RNA isolation and cDNA synthesis {#Sec4}
--------------------------------

Total RNA was isolated with TriZol reagent (Invitrogen, Carlsbad, CA) and samples were treated with Deoxyribonuclease I (Invitrogen) according to the manufacturer's protocol. To generate cDNA, 1 μg DNase-treated RNA was reverse-transcribed with the SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen) using oligo(dT) primer and 50 units SuperScript II, according to the manufacturer's protocol. After first-strand synthesis, samples were diluted to a final volume of 100 μl with water.

Conventional PCR {#Sec5}
----------------

Duplex PCR amplification of β*-actin* and *GAPDH* transcripts was carried out in a 25-μl reaction volume containing 2.5 μl of cDNA, 1× PCR Buffer (10 mM Tris--HCl pH 8.3, 50 mM KCl, 1.5 mM MgCl~2~), 100 μM each dNTP, 0.4 μM each primer, and 0.625 units Taq DNA polymerase (TaKaRa, Shiga, Japan). *β-actin* primers were as described \[[@CR12]\]. *GAPDH* primers (originally available from Clontech, Palo Alto, CA; kindly provided by Dr. B. Lethé) were 5′-TgAAggTCggAgTCAACggATTTggT-3′ (sense) and 5′-CATgTgggCCATgAggTCCACCAC-3′ (antisense). Cycling was performed in a TRIO-Thermoblock thermocycler (Biometra, Göttingen, Germany) as follows: 94°C for 4 min, followed by 22 cycles of 1 min at 94°C, 1 min at 65°C, and 1 min at 72°C. Cycling was concluded with a final extension step at 72°C for 15 min. PCR products were fractionated in 1.3% agarose gel and visualized by ethidium bromide fluorescence *(β-actin*, 626 bp; *GAPDH*, 983 bp). PCR amplification of *MAGE-A* transcripts was carried out with the primer pair designed by Zammatteo et al. \[[@CR13]\]. These primers derive from a consensus nucleotide sequence for the last exon of the 12 *MAGE-A* genes and give amplicons of \~539 bp. PCR conditions were as described above, except that PCR was performed for 30 cycles.

Quantitative real-time PCR {#Sec6}
--------------------------

Expression of CGGs and of the reference gene β-actin, was measured by quantitative PCR, based on TaqMan methodology, using the ABI PRISM 7700 Sequence Detection System (Applied Biosystems, Warrington, UK). PCR reactions were prepared with the qPCR Core Kit w/o dUTP reagents (Eurogentec, Seraing, Belgium). Each reaction (25 μl) contained 2.5 μl of cDNA, 1× PCR buffer containing the passive reference dye ROX, 5 mM MgCl~2~, 200 μM each dNTP, 200 nM each primer, 100 nM probe, and 0.625 units DNA polymerase. Primers, probes and thermal cycling conditions are given in Table [1](#Tab1){ref-type="table"} \[[@CR14], [@CR15]\]. Probes with 6FAM and TAMRA labels were from Eurogentec. Probes with 6FAM and MGB-NFQ labels (for MAGE-A3, MAGE-A6 and MAGE-A12) were from Applied Biosystems. Quantification of the samples was achieved by extrapolation from a standard curve of serial dilution points of cDNA of the relevant gene (Supplementary Figure 1). Samples and standard dilution points were assayed in duplicate or triplicate. Standard calibration curves for β-actin and all CGGs were linear over 4 (CGGs) or 5 (ß-actin) orders of magnitude and had similar PCR efficiencies (slope from −3.45 to −3.77). Differences in sensitivity between the assays for the various genes (*y*-intercept from 38.7 to 41.6) were due in part to differences in the actual cDNA copy number in the standard dilutions. cDNA copy numbers in the standards were verified by testing minimally 12 replicates of the 1-copy dilution in each qPCR run. If needed, copy numbers of the test samples were corrected by a factor calculated on the basis of the results for the 1-copy dilution. Normalization of samples was achieved by dividing the copy number of CGG by that of the reference gene, β-actin.Table 1Primers, probes and thermal cycling conditions of qPCRGeneForward primer (5′ → 3′)Reverse primer (5′ → 3′)Probe (5′ → 3′)Annealing-extenstionMAGEA1 \[[@CR15]\]gCC gAA ggA ACC TgA CCACT ggg TTg CCT CTg TCgTgT gTg CAg gCT gCC ACC TCC T90 s, 65°CMAGEA2 \[[@CR15]\]AAg TAg gAC CCg Agg CAC TggAA gAg gAA gAA gCg gTC TgCAT TgA Agg AgA AgA TCT gCC TgT ggg TCT TC1 min, 60°CMAGEA3 \[[@CR14]\]gTC gTC ggA AAT Tgg CAg TATgCA ggT ggC AAA gAT gTA CAAAAA gCT TCC AgT TCC TT1 min, 62°CMAGEA4 \[[@CR15]\]CCA CTA CCA TCA gCT TCA CTT gCCTT CTC ggA ACA Agg ACT CTg CAgg CAA CCC AAT gAg ggT TCC AgC1 min, 63°CMAGEA6gTC gTC ggA AAT Tgg CAg TgCA ggT ggC AAA gAT gTA CACTgC AAg gAA TCg gAA gC1 min, 65°CMAGEA10TAC TgC ACC CCT gAg gAg gTCTgT ggT ggC AAT TCT gTC CTgAAA Tgg gAg TgA TCC AAg ATC CTT CCC AC1 min, 64°CMAGEA12ggT ggA AgT ggT CCg CAT CggCC CTC CAC TgA TCT TTA gCA AAgg CAT CTg ATg ggA gg1 min, 60°CMAGEC2ggg AAT CTg ACg gAT Cgg AggA ATg gAA CgC CTg gAA CTgC TCC TgA AgA AgT CgT CAT gCC TCC1 min, 64°CGAGE1,2,8^a^CTA gAC CAA gAC gCT ACg TAg ACCC ATC Agg ACC ATC TTC ACACCT ATg Cgg CCC gAg CAg TTC Ag1 min, 62°CLAGE2/NY-ESO-1 \[[@CR15]\]CgC CTg CTT gAg TTC TAC CCAC TgC gTg ATC CAC ATC AAC ATCA gTA TgT TgC Cgg ACA CAg TgA ACT C1 min, 62°CACTB \[[@CR14]\]ATT gCC gAC Agg ATg CAg AAgTC ATA CTC CTg CTT gCT gATCA AgA TCA TTg CTC CTC CTg AgC gC1 min, 60°C^a^This assay detects GAGE1, GAGE2 and GAGE8

Immunohistochemistry {#Sec7}
--------------------

Immunochemistry was performed on 4 μm tissue sections of formalin-fixed paraffin-embedded tissue blocks. Sections were heated for 20 min in citrate buffer (10 mM, pH 6.0) for antigen retrieval. The following mouse IgG1 monoclonal antibodies (mAb) were used: E978 (anti-*NY-ESO-1*) \[[@CR16]\] (Zymed, San Francisco, CA), MA454 (anti-*MAGE-A1*) \[[@CR17]\] (Zymed, San Francisco, CA), and 57B (anti-*MAGE-A4*) \[[@CR18], [@CR19]\] (kindly provided by Dr. G.C. Spagnoli, University Hospital Basel, Switzerland). Testis tissue with intact spermatogenesis was used as positive control. Tissue sections were incubated with mAb diluted in PBA: E978 (2.5 μg/ml), MA454 (1 μg/ml), or 57B (5 μg/ml), or with IgG1 negative control antibody, at room temperature for 1 h. Binding sites of primary antibodies were then detected by a biotinylated horse-antimouse secondary reagent (Vector Laboratories, Burlingame, CA) followed by an avidin--biotin complex system (ABC Elite, Vector Laboratories). Diaminobenzidine tetrachloride served as a chromogen. Immunoreactivity was assessed blindly with respect to the mAb used.

Statistical analysis {#Sec8}
--------------------

Normalized CGG values are presented as means ± standard deviation (SD). The SD of the normalized CGG values was calculated from the SD of the CGG and the β-actin values using the following formula: CV = SQRT \[CV^2^~β-actin~ + CV~CGG~^2^\], where CV = SD/mean value (as described in the Sequence Detection System User Bulletin 2, 1997, Applied Biosystems). Differences in mRNA expression levels between pediatric and adult glioblastomas are calculated with the Spearman rank correlation. All statistical tests were two-sided, significance was determined as *P* \< 0.05.

Results {#Sec9}
=======

Study population {#Sec10}
----------------

We analyzed cancer-germline gene (CGG) expression in 50 fresh-frozen tumors by reverse transcription and polymerase chain reaction (PCR) amplification. All samples were histologically proven brain tumors from pediatric patients, ≤19-years old at the time of tumor resection and classified according to the WHO 2007 classification \[[@CR20]\] (Table [2](#Tab2){ref-type="table"}). An extra-cohort of nine glioblastoma samples from adult patients was also analyzed, for comparison to pediatric glioblastoma. Integrity of cDNA samples was verified by conventional, 22-cycle PCR amplification of a 626 bp *β-actin* and a 983 bp *GAPDH* product (data not shown). Samples were subjected to conventional PCR amplification with consensus primers for the 12 genes of the *MAGE-A* family. Twenty-seven samples were positive, indicating that, depending on the tumor type, 33--64% of the investigated pediatric tumors expressed at least one *MAGE-A* gene (Table [2](#Tab2){ref-type="table"}).Table 2Study groupTumor type^a^Number of patientsAverage age (range)% of *MAGE-A-*positive tumors^b^Medulloblastoma1112 years (4--19)55Ependymoma77 years (1--12)43Choroid plexus tumor54 years (1--10)40Pilocytic astrocytoma (WHO grade I)146 years (3--15)64Diffuse astrocytoma (WHO grade II)310 years (5--18)33Anaplastic astrocytoma (WHO grade III)513 years (7--19)60Glioblastoma (WHO grade IV)513 years (3--19)60Glioblastoma (WHO grade IV)^c^959 years (31--74)100^a^According to WHO 2007 classification \[[@CR20]\]^b^Gene expression was determined by conventional PCR with consensus primers for the 12 genes of the *MAGE-A* family^c^An extra cohort of adult patients with glioblastomas was studied to compare to pediatric glioblastomas (Fig. [2](#Fig2){ref-type="fig"})

CGG expression in pediatric brain tumors {#Sec11}
----------------------------------------

The 27 *MAGE*-*A*-positive samples were subsequently analyzed by quantitative real-time PCR (qPCR), using the TaqMan methodology, to measure the expression of the individual MAGE genes, *MAGE-A1*, *A2*, *A3*, *A4*, *A6*, *A10*, and *A12*. In addition, all 50 samples were tested by qPCR for expression of genes *MAGE-C2*, *NY-ESO-1* and *GAGE-1*,*2*,*8* (Table [2](#Tab2){ref-type="table"})*.* CGG expression levels were normalized to those of the *β-actin* gene (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Cancer-germline gene (CGG) expression in pediatric brain tumors measured by reverse transcription and quantitative real-time PCR. Each graph shows the results for one CGG in 50 different tumor samples. Samples are arranged in the same order in all graphs. The horizontal axis indicates the tumor type (Medullobl., medulloblastoma; Ependy., ependymoma; Plexus, plexus choroideus; Ast., astrocytic tumors grade I to IV). The bars represent normalized CGG expression values (CGG/*ß-actin* ratios)

*Medulloblastoma*. Six of the 11 medulloblastoma tumors expressed at least 1 of the 10 CGGs that were analyzed. The expression of CGGs in medulloblastomas was highly clustered (Table [3](#Tab3){ref-type="table"}). One sample expressed high levels (CGG/*ß-actin* ratios \> 10^−2^) of 6 CGG genes. The other medulloblastoma samples only sporadically expressed CGGs, with CGG/*ß-actin* ratios above 10^−4^.Table 3Clustered pattern of cancer-germline gene expression in medulloblastomasSampleMAGEA1MAGEA2MAGEA3MAGEA4MAGEA6MAGEA10MAGEA12MAGEC2NY-ESO-1GAGE1,2,81++++++++++−++++++++++++−+++++2−+++++−+−−−3−−−−+−++−−++4−−−−−−+−−−5−−−−−−+−−−6−−−+−−−−−−7−−−−−−−−−−8−−−−−−−−−−9−−−−−−−−−−10−−−−−−−−−−11−−−−−−−−−−The signs +, ++, +++, and ++++ represent CGG/ß-actin ratios ranging between 10^−5^ and 10^−4^, 10^−4^ and 10^−3^, 10^−3^ and 10^−2^, and \>10^−2^ (see Fig. [1](#Fig1){ref-type="fig"}). −, no CGG expression was detected

*Ependymoma*. Six out of seven ependymoma samples expressed at least 1 CGG. None expressed more than 3. Here the expression was therefore not clustered. Most positive samples expressed *NY-ESO-1* and/or *GAGE-1*,*2*,*8.* The overall levels of CGG expression in ependymoma samples were low, with CGG/*β-actin* ratios below 1 × 10^−3^.

*Choroid plexus tumor*. Of the five choroid plexus tumors analyzed, three showed no detectable CGG expression. Samples \#1 and \#2 expressed at least three CGGs. Only in one sample the CGG/*β-actin* ratio exceeded 1 × 10^−3^.

*Pilocytic astrocytoma*. Nine out of 14 pilocytic astrocytomas expressed at least one CGG. The overall expression was low, one low pilocytic astrocytoma had a CGG/*β-actin* ratio \>1 × 10^−4^.

*Diffuse astrocytoma*. Two out of three diffuse astrocytomas expressed at least one CGG. The overall expression level of CGGs on diffuse astrocytomas was low.

*High grade astrocytoma*. Eight out of 10 anaplastic astrocytomas and glioblastomas expressed at least one CGG. CGG/*β-actin* ratio in high grade astrocytomas did not exceed 1 × 10^−3^.

CGG expression in pediatric versus adult glioblastomas {#Sec12}
------------------------------------------------------

The relatively low expression of MAGE genes in high grade astrocytomas was unexpected since *MAGE* expression has been reported in almost all adult glioblastomas \[[@CR21]\]. In these studies different methods were used, immunohistochemistry \[[@CR21]--[@CR24]\] and conventional, non-quantitative PCR \[[@CR22]--[@CR24]\]. Therefore we decided to select nine new adult glioblastoma samples for *MAGE* qPCR analysis. All samples expressed at least five *MAGE-A* genes at high levels. The difference between the levels of *MAGE-A* genes expression in pediatric versus adult glioblastomas is shown in Fig. [2](#Fig2){ref-type="fig"} (*P* = 6.1 × 10^−6^).Fig. 2MAGE-A expression in pediatric and adult glioblastomas. Normalized MAGE-A expression levels (MAGE-A/*ß-actin* ratios) of seven MAGE-A genes are shown. Horizontal bars represent mean relative MAGE expression. Pediatric glioblastomas (*closed circles*) express significantly lower levels of MAGE-A compared to adult glioblastomas (*open circles*), *P* = 6.1 × 10^−6^ calculated with Spearman rank correlation

Cancer-germline protein distribution {#Sec13}
------------------------------------

Immunohistochemistry with monoclonal antibodies (mAbs) E978 (anti-NY-ESO--1), MA454 (anti-MAGE-A1) and 57B (anti-MAGE-A4) was performed on available paraffin-embedded tissues. Sections from normal testis tissue were used as positive controls. The intensity of the stainings correlated well with the level of CGG expression, as shown in Fig. [3](#Fig3){ref-type="fig"}a, b. The MAGE-A1, MAGE-A4 and NY-ESO-1 proteins were distributed homogenously throughout the tissues. However, a minority of the tissues had a heterogeneous staining pattern such as the MAGE-A4 expression in medulloblastoma sample \#1 (Fig. [3](#Fig3){ref-type="fig"}c). No staining could be observed for samples that scored either negative or with CGG/*β-actin* ratios below 10^−4^.Fig. 3(**a**) Amplification plots of three pilocytic astrocytomas in duplicate showing high numbers (H), low numbers (L) or no (N) MAGE-A4 cDNA copies. (**b**) Immunohistochemistry with mAb 57B (anti-MAGE-A4) of the pilocytic astrocytomas shown in **a**. A section of normal testis is used as a positive control. The intensity of the staining correlates with the amount of MAGE-A4 copies. (**c**) Immunohistochemistry with mAbs E978 (anti-*NY-ESO-1*), MA454 (anti-*MAGE-A1*), 57B (anti-*MAGE-A4*) and the IgG isotype negative control antibody on sections of medulloblastoma sample 1 (see Fig. [1](#Fig1){ref-type="fig"} for relative mRNA expression). Original magnification 63×. This sample was chosen because of the heterogeneous expression of the MAGE-A4 protein

CGG expression and tumor stage {#Sec14}
------------------------------

The number of patients in each specific group of tumors was too small to try to establish a correlation between CGG expression and clinicopathological parameters. Stratification of the pediatric astrocytic tumors in pilocytic astrocytoma (grade I), diffuse astrocytoma (grade II) and high grade anaplastic astrocytomas and glioblastomas (grade III and IV, respectively), revealed that the level of CGG expression was not significantly different between groups. These data suggest that CGG expression in astrocytic tumors is not correlated with the grade of the astrocytic tumor in pediatric patients.

Discussion {#Sec15}
==========

Antibodies and T cells can be identified that recognize antigenic fragments derived from gene products expressed by tumors \[[@CR10], [@CR25], [@CR26]\]. A critical role for these anti-tumor immune mechanisms in the eradication of cancer has been demonstrated in numerous animal models and some clinical trials \[[@CR27], [@CR28]\]. In the last decennia promising new strategies for the development of antibodies and activated T cells against tumor associated antigens have been developed \[[@CR29], [@CR30]\]. In spite of the blood brain barrier, there is accumulating evidence that even brain tumors can cause immune activation and are amenable for immunotherapy \[[@CR2], [@CR4], [@CR31]\].

The identification of immunogenic tumor associated antigens is an essential step in the development of rational cancer vaccines. The potential of CGGs as vaccine targets has led to detailed studies of their expression in various malignancies in adult patients \[[@CR10], [@CR32]\]. Previously, we reported on the expression of CGGs in pediatric extra-cranial tumors \[[@CR11]\]. Here we report that, in our cohort of 50 pediatric brain tumors, 68% expressed one or more CGGs. Immunohistochemical data correlated well with the qPCR results. Apart from a few exceptions, the overall level of CGG expression on pediatric brain tumors is low. Preliminary data from cytotoxicity assays indicated that glioblastoma cell lines that express low levels of CGGs (CGG/*β-actin* ratio \< 1 × 10^−4^) are not specifically lysed by HLA-matched anti-MAGE A3 CTL cell lines (data not shown).

In contrast to the limited CGG expression found in pediatric brain tumors, glioblastomas from adult patients express significantly higher levels of CGGs (*P* \< 0,001). This finding is in line with reported differences between adult and pediatric glioblastomas in p53 and EGFR expression \[[@CR33], [@CR34]\]. The differences in protein expression may be explained by chromosomal aberrations and differences in microsatellite stability between adult glioblastomas and pediatric glioblastomas \[[@CR35], [@CR36]\]. The significant difference in MAGE-A expression between adult and pediatric glioblastomas supports the view that these tumors develop along distinct genetic pathways.

In conclusion, we report limited CGG expression in pediatric brain tumors. Only a small percentage of brain tumors express high levels of CGGs. These data indicate that CGGs can only be used as immune target in a selected group of pediatric brain tumors.
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